Robbins Arroyo LLP: Lion Biotechnologies, Inc. (LBIO) Misled Shareholders According to a Recently Filed Class Action

SAN DIEGO & NEW YORK--()--Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Lion Biotechnologies, Inc. (NasdaqGM: LBIO) in the U.S. District Court for the Northern District of California. The complaint is brought on behalf of all purchasers of Lion securities between November 14, 2013 and April 10, 2017, for alleged violations of the Securities Exchange Act of 1934 by Lion's officers and directors. Lion, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/lion-biotechnologies-inc

Lion Accused of Engaging in Illegal Stock Promotion Scheme

According to the complaint, Lion attested in its public filings to the accuracy of financial reporting, the disclosure of any material changes to the company's internal controls over financial reporting, and the disclosure of all fraud. On May 14, 2014, Lion stated in its 1Q 2014 Form 10-Q that it received a subpoena from the U.S. Securities and Exchange Commission ("SEC") seeking information concerning "documents and communications related to individuals who post or have posted articles regarding the Company on equity research or other financial websites." On April 10, 2017, the SEC found that Lion, through its former Chief Executive Officer Manish Singh ("Singh") engaged in a scheme to mislead investors by commissioning over ten internet publications and 20 widely distributed emails promoting Lion to potential investors that purported to be independent from the company, when, in fact, they were paid promotions. Further, Singh engaged a stock promotion firm to pay writers to publish articles about Lion on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes.

Lion Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com

Release Summary

Do you own shares of Lion Biotechnologies, Inc.? Robbins Arroyo LLP is investigating claims on behalf of shareholders of Lion.

$Cashtags

Contacts

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com